Clinical Trial Update: PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer [Phase 2]

View source ↗

Summary

Phase II trial of ganetespib (STA-9090) as second- or third-line therapy for metastatic pancreatic cancer was terminated; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Ganetespib (STA-9090) (ganetespib)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-07-23